# OReO (NCT03106987)

> A Study to Examine Olaparib Maintenance Retreatment in Patients With Epithelial Ovarian Cancer.

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03106987
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: AstraZeneca
- Conditions: Epithelial Ovarian Cancer
- Interventions: Active Comparator: Olaparib tablets; Placebo
- Enrollment: 220
- Primary outcome: Efficacy: Progression-free Survival (PFS)

## Commentary we found

- YouTube: 16
- Podcasts: 10
- X threads: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=oreo-nct03106987

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03106987", "email": "<work email>"}; the inbox owner confirms by the emailed link.